6th IAS Conference
18th CROI
11th Int Workshop on Clin Pharm of HIV
17th CROI
5th IAS Conference
16th CROI
Ninth Int Congress on Drug Therapy in HIV Infection
XVII International AIDS Conference
15th CROI
4th IAS Conference

Archives

Last Update:  August 08, 2011
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

• POSTER
  Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal:
  the DAYANA Trial, IMEA032/ANRS12115
  R. Landman, S. Koulla-Shiro, P.-S. Sow, et al
  Poster     Abstract
• POSTER
  Key considerations for successful implementation of the 2010 PMTCT guidelines in Rwanda - tenofovir (TDF) based highly active antiretroviral treatment (HAART) extended during breastfeeding regimens in Rwanda
  I. Ange Anitha, S.U. Nadine, N. Jean Pierre, et al
  Poster     Abstract
• POSTER
  Differences in renal function and toxicity between antiretroviral-naive and experienced HIV-infected patients initiating a tenofovir containing regimen
  P. Wikman, M. Pérez-Elías, P. Safont, et al
  Poster     Abstract
• POSTER
  A prospective study of changes in serum lipid profile among people living with HIV/AIDS on PI based second line ART regimen
  R. De, S. Bhandari, M. Mahato, et al
  Poster     Abstract
• POSTER
  Substituting drugs within first-line regimen at hospitals and health centers: an observational cohort assessment in rural Lesotho
  N.D. Labhardt, M. Sello, J. Ehmer, et al
  Poster    Abstract
• POSTER
  Impact of tenofovir-associated renal dysfunction among HIV-infected patients with low body-weight: a retrospective cohort study of the Japanese patients
  T. Nishijima, H. Komatsu, H. Gatanaga, et al
  Poster     Abstract
• POSTER
  Enrollment, follow-up, and risk behavior of injecting drug users in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial
  in Bangkok, Thailand
  K. Choopanya, S. Vanichseni, P. Suntharasamai, et al
  Poster     Abstract
• POSTER
  Morbidity and mortality of injecting drug users participating in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in
  Bangkok, Thailand
  S. Vanichseni, M. Martin, P. Suntharasamai, et al
  Poster     Abstract
• POSTER
  Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort (2004-2008)
  P. Morlat, A. Vivot, F. Dauchy, et al
  Poster     Abstract
• Virological efficacy of the four tenofovir-containing WHO-recommended regimens for initial antiretroviral therapy
  M. Tang, P. Kanki, R. Shafer, et al
  Abstract
• Explaining the CAPRISA 004 results: tenofovir as a double-targeted HIV-1/HSV-2 antiviral
  A. Graciela, A. Lisco, C. Vanpouille, et al
  Abstract
• Preventing HIV and herpes infections: predicting the impact of the CAPRISA tenofovir gel in KwaZulu-Natal, South Africa
  D.J. Gerberry, B.G. Wagner, J.G. Garcia-Lerma, et al
  Abstract
• Case-controlled study of Fanconi syndrome (FS) in HIV-infected patients receiving tenofovir DF (TDF)
  S. Gupta, C. Wyatt, A. Rachlis. et al
  Abstract
• Changes in natural killer cell activation and function in early HIV infection
  V. Naranbhai, M. Altfeld, L. Werner, et al
  Abstract
• In vivo inhibition of HIV-1 infection at mucosal sites by an anti-HIV CCR5 targeting vector: potential use as an HIV microbicide
  J. Walker, J. McGee, G. Bauer. et al
  Abstract
• Potent HBV therapy and availability of laboratory monitoring fail to abrogate increased risk of death in HBV-HIV-co-infected individuals
  in the DART study
  H. Price, R. Gilson, D. Pillay, et al
  Abstract
• Strengthening health systems for HIV prevention: integrating quality improvement and family planning services with 1% tenofovir gel
  provision in the CAPRISA 008 phase IIIB randomized controlled implementation trial
  K. Torjesen, K. Mate, L. Mansoor, et al
  Abstract
• Acute pre-seroconversion HIV infection at baseline prior to starting oral or topical pre-exposure prophylaxis: iPrEx and CAPRISA 004
  R. Grant, Q. Abdool Karim, T. Liegler, et al
  Abstract
• Ultra-short cycles of quadruple anti reverse transcriptase combinations, 2 days or 1 day a week, as effective maintenance treatment in
  HIV-1 infection
  J.P.L. Leibowitch, D. Mathez, P. de Truchis, et al
  Abstract
• Evaluating different strategies for transitioning patients from stavudine to tenofovir in resource-constrained settings
  P. Grant, A. Talbot, E. Bendavid, et al
  Abstract
• Novel pattern of treatment-emergent lipid and renal abnormalities in antiretroviral naïve patients in the multi-centre Canadian Observational
  Cohort (CANOC)
  K. Johns, M. Harris, D. Milan, et al
  Abstract
• Evolution of kidney tubular dysfunction (KTD) in a prospective cohort of HIV+ patients on prolonged exposure to tenofovir
  P. Labarga, P. Barreiro, S. Rodriguez-Novoa, et al
  Abstract
• Determination of kidney function prior to tenofovir initation: four-fold difference in need of tenofovir dose reduction depending on method used
  C. Mony Kim, T. Phe, T. Sopheak, et al
  Abstract
• Incidence and prevalence of serum hypophosphatemia in a large cohort of HIV-infected patients
  M. del Palacio, J.M. Rodríguez, A. Moreno, et al
  Abstract
• Risk of antiretroviral-associated renal toxicity in HIV\-infected patients with altered basal renal function
  P. Safont Gasó, P. WIkman, M. del Palacio, et al
  Abstract
• Risk factors for K65R development in mexican patients failing to multiple antiretroviral (ARV) combinations
  F.Y. García Kishi, E. Vidal-Laurencio, W. Moncada, et al
  Abstract
• Rate and risk factors of anti-tuberculous drug-associated hepatotoxicity in advanced HIV/TB Co-infected patients
  W. Manosuthi, A. Lueangniyomkul, W. Mankatitham, et al
  Abstract

• POSTER
  TDF Therapy Is Independently Associated to Hyperparathyroidism in HIV-infected Treated Patients
  D Pocaterra, L Carenzi, E Ricci,  et al
  PDF Poster     Abstract
• POSTER
  Renal Insufficiency, Nephrotoxicity, and Mortality among HIV-infected Adults on TDF in a South African
  Cohort: A Marginal Structural Models Analysis
  A Brennan, D Evans M Fox, et al
  PDF Poster     Abstract
• POSTER
  Renal Impairment in Patients Receiving a TDF-based cART Regimen: Impact of TDF Concentration?
  I Poizot-Martin, C Solas, J Allemand, et al
  PDF Poster     Abstract
• POSTER
  A Global Clinical Comparison of TDF+3TC+NVP vs TDF+3TC+EFV in Resource-constrained Populations
  M Etienne-Mesubi, A Amoroso A Edozien, et al
  PDF Poster     Abstract
• POSTER
  Resistance Profiles of FTC and 3TC in TDF-containing Regimens
  A-G Marcelin, C Charpentier, M Wirden, et al
  PDF Poster     Abstract
• POSTER
  Renal Insufficiency Risk among HIV⁺, ART-naïve Individuals in Lilongwe, Malawi: Implications for TDF
  Use in ART and PMTCT Programs
  D J ohnson, C Chasela, M Maliwichi, et al
  PDF Poster     Abstract
• POSTER
  ACTG A5249s: Time to Onset of First-phase Viral Decay in Antiretroviral-naïve Patients Treated with RAL
  and FTC/TDF
  A Andrade, S Rosenkranz, D Lu, et al
  PDF Poster     Abstract
• POSTER
  Switching ZDV to TDF Improves Subcutaneous Adipose Tissue Volume and mtDNA Content
  E Feeney, S Vrouenraets, F Wit, et al
  PDF Poster     Abstract
• POSTER
  Pharmacogenetics of Change in cCrCl with Regimens Containing TDF in ACTG Study A5202
  H Ribaudo, E Daar, C Tierney, et al
  PDF Poster     Abstract
• POSTER
  What Impact Would Introduction of a TDF Vaginal Microbicide Have on Incidence of HIV in Women and Men
  in Southern Africa?
  V Cambiano, D Bennett, G Garnett, et al
  PDF Poster     Abstract
• POSTER
  Near Perfect Early Adherence to Antiretroviral PrEP against HIV Infection among HIV Serodiscordant Couples
  as Determined by Multiple Measures: Preliminary Data from the Partners PrEP Study
  J Haberer, J Baeten, C Celum,  et al
  PDF Poster     Abstract
• Pharmacokinetics of TDF in Blood Plasma and Cervicovaginal Fluid of HIV+ Post-menopausal Compared
  with Pre-menopausal Women
  K Patterson, J Dumond, H Prince,  et al
  Abstract
• Significant Liver Fibrosis Is an Independent Risk Factor of Renal Impairment in HIV/HBV Co-infected
  Patients Treated with TDF: Results of a 3-Year Cohort Study
  K Lacombe, As Boyd, E Lasnier, et al
  Abstract
• Vitamin D3 Supplementation Decreases PTH in HIV-infected Youth Being Treated with TDF-containing
  Combination ART: A Randomized, Double-blind, Placebo-controlled Multicenter Trial: Adolescent Trials
  Network Study 063
  P Havens, R Hazra, C Stephensen, et al
  Abstract
• Central Fat Accumulation in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV:
  ACTG A5224s, a Substudy of ACTG A5202
  G McComsey, D Kitch, P Saxm et al
  Abstract
• BMD Loss in HIV^– Men Participating in a TDF PrEP Clinical Trial in San Francisco
  A Liu, E Vittinghoff, R Irby, et al
• Abstract
  Influence of HIV Infection on the Efficacy of TDF as an Anti-HBV Agent in 3TC-experienced Patients
  E Poveda, Z Plaza, A Aguilera,  et al
  Abstract
• Oral TDF and Its Impact in HSV-2 Acquisition and Clinical Expression
  J Lama, K Maye, M Schechter, et al
  Abstract
• Interpreting Detection Rates of Intracellular FTC-TP and TFV-DP: The iPrEx Trial
  P Anderson, J Lama, S Buchbinde, et al
  Abstract
• Renal Insufficiency Risk among HIV⁺, ART-naïve Individuals in Lilongwe, Malawi: Implications for TDF
  Use in ART and PMTCT Programs
  D Johnson C Chasela, M Maliwichi,  et al
  Abstract

• PDF ABSTRACT
  Impact of age on renal function in patients receiving tenofovir 
  L. Goeddel, K.W. Crawford, R. Moore, et al 
• PDF ABSTRACT
  Tenofovir disoproxil fumarate (TDF) pharmacokinetics (PK) with increased doses in HIV-1
  infected pregnant women and their newborns (HPTN 057)
  M. Mirochnick, N. Kumwenda, E. Joao,  et a
• PDF ABSTRACT
  Tenofovir population pharmacokinetics in HIV-infected children and adolescents
  J. King,  R. Yogev, A. Wiznia,  et al